---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-018651"
form_type: "8-K"
ticker: "LSTA"
cik: "0000320017"
company_name: "LISATA THERAPEUTICS, INC."
filed_at: "2026-05-04T23:59:59+00:00"
generated_at: "2026-05-15T00:07:48.656105+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Lisata extends tender offer deadline to May 29; Kuva to pay up to $1.1M in expenses

## Summary
- Tender offer commencement extended from April 13 to May 29, 2026, under amended merger agreement.
- Kuva Labs to pay Lisata up to $1.1M via five interim payments: $175k on May 5, $175k on May 7, $250k on May 12, $250k on May 19, $250k on May 26.
- Lisata agrees not to sue Kuva until May 29; waives all claims for failure to start offer by April 13 upon commencement and payment of interim amounts.
- Waiver terminates if Kuva fails to make any interim payment when due or commits an uncured material breach.
- Original merger agreement signed March 6, 2026; deal remains subject to regulatory and stockholder conditions.

## SEC filing metadata
- accession: 0001140361-26-018651
- form_type: 8-K
- ticker: LSTA
- cik: 0000320017
- company_name: LISATA THERAPEUTICS, INC.
- filed_at: 2026-05-04T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/320017/000114036126018651/0001140361-26-018651-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/320017/000114036126018651/ef20072320_form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-018651
- JSON: https://secwatch.observer/filing/0001140361-26-018651.json
- Plain text: https://secwatch.observer/filing/0001140361-26-018651.txt

## Source-grounded claims
- claim_id: b280ea7d042964e48452e94f7aeba2351c1fffdb
  claim: LISATA THERAPEUTICS, INC. amended Amendment and Waiver with Kuva Labs Inc. and Kuva Acquisition Corp. valued at up to $1.1 million (effective 2026-05-03).
  evidence_excerpt: On May 3, 2026, Lisata Therapeutics, Inc. (the “Company” or “Lisata”) and Kuva Labs Inc., a Delaware corporation (“Parent”), together with Kuva Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”), entered into an amendment and waiver (the “Amendment and Waiver”) to the previously announced Agreement and Plan of Merger, dated as of March 6, 2026, by and among Parent, Purchaser and the Company (the “Merger Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/320017/000114036126018651/0001140361-26-018651-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.